Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Status Not yet recruiting

Clinical Trial Summary

This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

Clinical Trial Description

Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05679921
Study type	Interventional
Source	Yonsei University
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	March 1, 2024
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02910895` - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)	N/A
Recruiting	`NCT05621668` - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma	Phase 1
Active, not recruiting	`NCT04032964` - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS	Phase 1
Active, not recruiting	`NCT04577014` - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT01650077` - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT02204111` - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn	`NCT01663090` - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas	N/A
Completed	`NCT01440088` - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Phase 3
Completed	`NCT01259375` - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma	Phase 2
Completed	`NCT01106872` - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Phase 1
Recruiting	`NCT00753727` - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma	Phase 1/Phase 2
Terminated	`NCT00755261` - Phase II Study of Doxorubicin and Avastin® in Sarcoma.	Phase 2
Completed	`NCT00611078` - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study	N/A
Completed	`NCT00580320` - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Phase 1
Completed	`NCT03452644` - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting	`NCT05539677` - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3